Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE
Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
How this was made
The 30-second read
Why it matters
Earnings and M&A news provide fresh catalysts, likely supporting short‑term bullish bias across the sector.
Market read
The collective earnings and deal news create a bullish backdrop for biotech equities, with potential spillover into broader health‑care indices.
What to watch
Potential regulatory or reimbursement risks for new product launches could temper upside.
Background
A roundup of biotech companies hitting 52‑week highs after reporting earnings, guidance updates, product launches, and a major acquisition.
Ticker impact
MiniMed reported FY2026 net sales of $843M and a 10.5% organic growth outlook, driving a 10% intraday rise to a 52‑week high.
Potential further upside if guidance holds.
Strong sales growth and new product launch signal continued momentum.
Pulse Biosciences posted Q2 revenue of $0.4M and highlighted commercial launch progress, sending the stock 3% higher to a 52‑week high.
Modest upside as product adoption expands.
Revenue remains modest but launch milestones may attract investors.
Solventum posted Q2 revenue of $2.21B, net income $92M and raised full‑year guidance, pushing the share to $94.16, a 52‑week high.
Likely continued upward bias if guidance is met.
Revenue growth and guidance lift are material for a mid‑cap med‑tech name.
Royalty Pharma reported Q2 royalty receipts of $768M (14% growth) and a $100M funding deal with Zealand Pharma, lifting the stock to a 52‑week high.
Supportive for near‑term price stability.
Revenue growth and strategic funding enhance cash flow outlook.
Apogee disclosed a definitive acquisition agreement by AbbVie valued at $10.9B and reported Q2 loss of $85.9M, sending the stock to a 52‑week high.
Share price likely to remain elevated pending deal completion.
Large acquisition premium and strategic fit outweigh loss reporting.
Market effects
Broad biotech sector gains from multiple earnings beats and guidance raises.
U.S. biotech equities see heightened buying pressure.
Positive earnings news may lift global health‑care indices.
Counterpoint
Some investors may view the rapid price spikes as overbought and anticipate pull‑backs.
Key entities
- companyMiniMed Group Inc.
Diabetes technology firm reporting strong FY2026 sales.
- companyPulse Biosciences Inc.
Bioelectric medicine company with early commercial launch progress.
- companySolventum Corporation
MedTech services provider raising full‑year guidance.
- companyRoyalty Pharma plc
Royalty acquisition firm reporting robust royalty receipts.
- companyApogee Therapeutics Inc.
Biotech firm being acquired by AbbVie.
